• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Critical heart drug too pricey for some Medicare patients

Bioengineer by Bioengineer
July 22, 2019
in Chemistry
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers say cost may be more than $1,600 after insurance payments

An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A. Burns School of Medicine (JABSOM) researcher at the University of Hawaii at Manoa.

The therapy is a combination of sacubitril/valsartan called Entresto®. Researchers found that, even with insurance, the cost to Medicare patients may be more than $1,600 a year.

“This drug is the standard of care for the people with significant congestive heart failure according to both the American Heart Association and American College of Cardiology guidelines, yet it’s priced so high that, even with insurance, patients may not be able to afford it,” said senior author Chien-Wen Tseng, HMSA Endowed Chair in Health Services and Quality Research at JABSOM and physician investigator with Honolulu’s Pacific Health Research and Education Institute.

The study co-authors worry that, since Entresto® is a pricey, brand-name drug, such high copayments may result in patients not taking it at all. And that comes with a steep price.

“The science shows that this drug can help save lives,” said Tseng, pointing to clinical studies showing the therapy has reduced deaths from heart failure by 20 percent. “We need to figure out a way to deal with its $5,000 price tag, and how folks on Medicare can afford to pay $1,600 each year in copayments to benefit from it.”

Current laws prohibit the U.S. Department of Health and Human Services from negotiating drug prices with pharmaceutical companies on behalf of Medicare Part D beneficiaries. As a result, said lead researcher Colette DeJong of the University of California at San Francisco, “Paying $1,600 per year for a single drug could be a huge hardship for many older adults who lived on an average income of less than $25,000 in 2017. Changing the laws that prevent Medicare from negotiating drug prices on behalf of seniors and people living with disabilities would be one step toward curbing these skyrocketing out-of-pocket costs.”

###

For more information, visit: http://go.hawaii.edu/bsG

Media Contact
Tina Shelton
[email protected]

Related Journal Article

https://jabsom.hawaii.edu/medicare-patients-may-not-be-able-to-afford-life-saving-heart-failure-drug-says-jama-cardiology-study-uhs-dr-chien-wen-tseng-a-co-author/
http://dx.doi.org/10.1001/jamacardio.2019.2223

Tags: AgingCardiologyGerontologyMedical/Scientific EthicsMedicine/HealthPharmaceutical ScienceStroke
Share12Tweet8Share2ShareShareShare2

Related Posts

Bright Excitons Enable Optical Spin State Control

Bright Excitons Enable Optical Spin State Control

August 3, 2025
blank

Flame Synthesis Creates Custom High-Entropy Metal Nanomaterials

August 2, 2025

Innovative Acid-Base Bifunctional Catalyst Enhances Production of Essential Lithium-Ion Battery Material

August 1, 2025

Oven-Temperature Treatment (~300℃) Enhances Catalyst Performance by Six Times

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    49 shares
    Share 20 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Weight-Adjusted Waist Index Predicts Breast Cancer

Institutional Factors Impacting Cervical Cancer Guideline Compliance

Bright Hybrid Excitons Boost Scalable X-ray Scintillators

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.